Literature DB >> 14526386

Target discovery.

Mark A Lindsay1.   

Abstract

Target discovery, which involves the identification and early validation of disease-modifying targets, is an essential first step in the drug discovery pipeline. Indeed, the drive to determine protein function has been stimulated, both in industry and academia, by the completion of the human genome project. In this article, we critically examine the strategies and methodologies used for both the identification and validation of disease-relevant proteins. In particular, we will examine the likely impact of recent technological advances, including genomics, proteomics, small interfering RNA and mouse knockout models, and conclude by speculating on future trends.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526386     DOI: 10.1038/nrd1202

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  70 in total

Review 1.  PubChem as a public resource for drug discovery.

Authors:  Qingliang Li; Tiejun Cheng; Yanli Wang; Stephen H Bryant
Journal:  Drug Discov Today       Date:  2010-10-21       Impact factor: 7.851

2.  Optimization of drug combinations using Feedback System Control.

Authors:  Patrycja Nowak-Sliwinska; Andrea Weiss; Xianting Ding; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Chih-Ming Ho
Journal:  Nat Protoc       Date:  2016-01-14       Impact factor: 13.491

3.  Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

Authors:  André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Determining the functional role of TRPC channels in primary cells.

Authors:  Su Li; Martin Gosling; Chris Poll
Journal:  Pflugers Arch       Date:  2005-08-03       Impact factor: 3.657

5.  Screening phage display libraries for organ-specific vascular immunotargeting in vivo.

Authors:  Philippe Valadon; Jeff D Garnett; Jacqueline E Testa; Marc Bauerle; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-29       Impact factor: 11.205

6.  VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes.

Authors:  Ruben Papoian; Andreas Scherer; Muriel Saulnier; Frank Staedtler; André Cordier; Francois Legay; Gerard Maurer; Joerg Staeheli; Jacky Vonderscher; Salah-Dine Chibout
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

7.  Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Heidi Y Zhang; Li-Chia Feng; Brian D Piening; Leigh Anderson; Amanda G Paulovich
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365

8.  Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo.

Authors:  Jacqueline E Testa; Adrian Chrastina; Phil Oh; Yan Li; Halina Witkiewicz; Malgorzata Czarny; Tim Buss; Jan E Schnitzer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-22       Impact factor: 5.464

9.  Identifying the proteins to which small-molecule probes and drugs bind in cells.

Authors:  Shao-En Ong; Monica Schenone; Adam A Margolin; Xiaoyu Li; Kathy Do; Mary K Doud; D R Mani; Letian Kuai; Xiang Wang; John L Wood; Nicola J Tolliday; Angela N Koehler; Lisa A Marcaurelle; Todd R Golub; Robert J Gould; Stuart L Schreiber; Steven A Carr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

10.  Update of TTD: Therapeutic Target Database.

Authors:  Feng Zhu; BuCong Han; Pankaj Kumar; XiangHui Liu; XiaoHua Ma; Xiaona Wei; Lu Huang; YangFan Guo; LianYi Han; ChanJuan Zheng; YuZong Chen
Journal:  Nucleic Acids Res       Date:  2009-11-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.